S100A4 promotes colon inflammation and colitis-associated colon tumorigenesis

Jinhua Zhang a,4, Shasha Hou a,4, Jianchun Gu b, Tian Tian a, Qi Yuan a, Junying Jia c, Zhihai Qin d, and Zhihan Chen a,5

a College of Life Science and Bioengineering, Beijing Jiaotong University, Beijing, P.R. China; b Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China; c Core Facility Center, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China; d Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, P. R. China; e Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer, Fourth Military Medical University, Xi’an, P. R. China

ABSTRACT

S100A4 plays important roles in tumor development and metastasis, but its role in regulating inflammation and colitis-associated tumorigenesis has not been well characterized. Here, we report that S100A4 expression was increased in azoxymethane (AOM) and dextran sulfate sodium (DSS) induced colorectal cancer (CRC) in mice. After AOM/DSS treatment, both S100A4-TK mice with the selective depletion of S100A4-expressing cells and S100A4-deficient (S100A4−/−) mice developed fewer and smaller tumors than wild-type (WT) control littermates. Furthermore, S100A4−/− mice were resistant to DSS-induced colitis, reduced infiltration of macrophages, and the diminished production of proinflammatory cytokines. Further studies revealed that reduced colon inflammation and colorectal tumor development in S100A4−/− mice were partly due to the dampening of nuclear factor (NF)-κB activation in macrophages. Furthermore, the administration of a neutralizing S100A4 antibody to WT mice significantly decreased AOM/DSS-induced colon inflammation and tumorigenesis. These results indicate that S100A4 amplifies an inflammatory microenvironment that promotes colon tumorigenesis and provides a promising therapeutic strategy for treatment of inflammatory bowel disease and prevention of colitis-associated colorectal carcinogenesis.

Introduction

Chronic inflammation is a major driving force for the initiation and progression of many types of cancers, including colorectal cancer (CRC), lung cancer, and hepatocellular carcinoma (HCC). CRC is the third most common form of cancer and the second leading cause of cancer-related death in developed countries. Patients with inflammatory bowel diseases (IBDs) such as ulcerative colitis (UC) and Crohn’s disease (CD) are at an increased risk for the development of CRC. UC increases the cumulative risk of colitis-associated colorectal cancer (CAC) by up to 18–20%, while CD increases it up to 8%, after 30 years of disease. It has been reported that cytokines, chemokines, matrix-degrading enzymes, and growth factors produced during chronic inflammation in IBD patients are proposed to damage DNA and/or alter cell proliferation or survival, thereby promoting cancer development. Immune cells, which often infiltrate tumors and preneoplastic lesions, also produce a variety of cytokines and chemokines that propagate a localized inflammatory response and enhance premalignant cell growth and survival by activating signaling pathways such as nuclear factor (NF)-κB or mitogen-activated protein kinases (MAPKs). However, the underlying mechanisms that link these chronic inflammatory states to colorectal cancer development need to be further explored.

S100A4 is a member of the S100 calcium-binding protein family. Previous studies have reported that S100A4 is expressed in a variety of cells, such as fibroblasts, macrophages, and malignant cells, and plays a crucial role in mediating tumor-stromal interplay. S100A4 functions as both intracellular and extracellular forms. Intracellular S100A4 is involved in a wide range of biological functions, such as the regulation of angiogenesis, cell survival, motility, invasion or metastasis. However, the secretion of S100A4 by tumor and stromal cells is believed to serve as a key player in promoting the metastasis of cancer cells or affecting angiogenesis. Studies have shown that some cytokines, particularly chemokine (C-C motif) ligand 5 (CCL5), are necessary and sufficient for inducing the release of S100A4 from fibroblasts contributing to the formation of pre-metastatic niches. Furthermore, it has been demonstrated that the ablation of S100A4 in stromal cells significantly reduced metastatic colonization by regulating matrix protein tenascin-C and growth factor vascular endothelial growth factor (VEGF)-A. In previous studies, we found an additional mechanism of
action that S100A4+ fibroblasts promote skin carcinogenesis by maintaining MCP-1-mediated macrophage infiltration and chronic inflammation.20 In addition, we identified a critical role of S100A4 in promoting liver fibrosis through hepatic stellate cell activation,21 and macrophage-derived S100A4 promotes liver carcinogenesis by promoting CD8+ T-cell survival (unpublished).

Previous studies have reported that the overexpression of S100A4 is closely associated with the progression of colorectal cancer.33 High S100A4 levels in colorectal tumors are associated with metastasis, poor prognosis, and shortened patient survival times.34 Recently, we found S100A4 promotes colitis development by enhancing host adhesion and colonization of Citrobacter rodsentium through the S100A4-mediated host inflammatory responses.35 Given the importance of S100A4 in tumor biology and inflammation, we questioned whether S100A4 contributes to inflammation-related colon tumorigenesis. The mouse model of colitis-associated colon cancer, which is induced by the administration of azoxymethane (AOM) followed by repeated oral administration of dextran sulfated sodium (DSS), has been highly informative.36 Using the AOM/DSS mouse model, we showed here that S100A4 played key roles in the progression of IB and CRC. We found that many S100A4+ cells infiltrated into the colon in colitis and CRC model mice. Selective depletion of S100A4+ cells and deficiency of S100A4 or blockade of S100A4 by neutralizing antibody significantly alleviated the disease severity in murine models of colitis and decreased tumor incidence in a murine model of CRC. Mechanistic study revealed that up-regulated S100A4 played an important function in inflammation via recruiting macrophages. In turn, NF-κB signaling in macrophages activated by S100A4 results in a vicious cycle of chronic inflammation, which promotes the occurrence of CRC. Our study suggests that S100A4 is an important molecule involved in inflammation and carcinogenesis, which can be a therapeutic target in the treatment of inflammatory bowel disease and prevention of CRC.

Results

S100A4 expression is upregulated in mouse model of CRC tumors

The association between S100A4 expression and CRC has been reported using tumor samples from CRC patients.34,37 To further investigate the kinetics of S100A4+ cells during CRC development, which could not be studied using clinical samples, C57 BL/6 mice were administered AOM/DSS (Fig. 1A) that has been used to induce a two-stage carcinogenesis model for CRC. The dynamic changes in S100A4+ cells in the colon tissue of C57 BL/6 mice before and at different times after the AOM/DSS application were examined. As shown in Fig. 1B, there were few S100A4+ cells in the untreated colon. However, the number of S100A4+ cells was increased significantly after AOM/DSS treatment. IHC analysis revealed that S100A4 was mainly expressed in stromal cells located in the lamina propria throughout colon tissues and in the submucosal regions. In addition, S100A4 was also expressed in the lymphoid follicle (Fig. 1C). Furthermore, as shown in Fig. 1D-E, the expression of S100A4 was much higher in AOM/DSS-induced tumor-associated stroma than untreated colonic crypts.

The appearance of S100A4+ cells in the process of colitis and CRC suggests that they may play important roles in local inflammation and CRC development.

S100A4 is expressed in different types of cells during colitis

Next, we characterized the cellular source of S100A4 in the colon. S100A4+/TK+ GFP transgenic mice expressing green fluorescent protein (GFP) under the control of the S100A4 promoter38 were treated with DSS, and then cells were isolated from colon tissues, were co-stained with cellular marker antibodies for various cell types and were analyzed by flow cytometry. As shown in Fig. 2A, B, among the S100A4-GFP+ cells, approximately 97.9% were CD45+, mainly S100A4+ GFP+ cells expressing myeloid cell markers, 54.3% were CD11b+, 44.2% were F4/80+, 25.7% were CD11c+. In addition, a small number of the S100A4-GFP+ cells expressed markers of B cells, T cells and granulocytes (Fig. 2A and 2B). S100A4 was seldom expressed in epithelial cells, immunostaining of the colon tissues showed similar results (Fig. 2C). In addition, double staining revealed that most of the S100A4+ cells were not α-SMA positive, showing that they were not fibroblasts (Fig. S1).

Using LPS-induce colitis model, we also found that S100A4 was upregulated significantly in colon tissues and was expressed mainly in CD11b+ myeloid cells upon stimulation with LPS (Fig. S2).

S100A4 has been reported to be secreted out of cells through unknown mechanisms and to function as an inflammatory cytokine.21,29,30 To test whether S100A4 is secreted by S100A4+ cells in the CRC tissue, CD11b+ S100A4+ cells were isolated from DSS-treated colon tissues and were cultured in vitro, and the supernatant was analyzed for S100A4 by ELISA. CD11b+ S100A4+ cells were used as control. Indeed, soluble S100A4 was detected in the supernatant of CD11b+ S100A4+ cells but not in that of CD11b- S100A4+ cells (Fig. 2D). These results indicate that S100A4+ cells have many cellular origins in the colon during colitis and S100A4 can be secreted into the extracellular space.

Selective depletion of S100A4+ cells attenuates colon carcinogenesis

To explore the role of S100A4+ cells in the development of CRC, S100A4-thymidine kinase (TK) transgenic mice were used,22,29 and proliferating S100A4+ cells in these mice could be selectively depleted upon the treatment of ganciclovir (GCV) after the administration of AOM/DSS, as illustrated in Fig. 3A. Expression of the Ki67 antigen in S100A4+ cells indicated that these S100A4+ cells were proliferating, rendering them susceptible to depletion by GCV in S100A4-TK transgenic mice (Fig. 3B). As anticipated, the number of infiltrated S100A4+ cells in the colon, was decreased dramatically in S100A4-TK+ mice after GCV treatment for 2 weeks while this did not occur in control littermates (Fig. 3C). This reduction of S100A4+ cells in colon correlated with an attenuated accumulation of inflammatory cells in colon tissue, as shown by H&E staining (Fig. 3C). Importantly, GCV treatment in S100A4-TK+ mice attenuated colon tumorigenesis with a reduced
tumor number and size compared with the control group (Fig. 3D-G). Pathologic analysis revealed that GCV-treated S100A4-TK+ mice had smaller tumor areas than S100A4-TK− mice (Fig. 3H). S100A4-TK− mice had much more S100A4+ cells than S100A4-TK+ mice (Fig. 3I).

Moreover, the number of Ki67+ proliferating cells in colon tumors was also significantly reduced in GCV-treated S100A4-TK+ mice (Fig. 3H and 3I). These results suggest that the selective depletion of proliferating S100A4+ cells in colons significantly decreased colon tumorigenesis.

**Genetic deletion of S100A4 prevents colitis-associated colorectal tumorigenesis**

To further explore the role of S100A4 in colitis-related colorectal carcinogenesis, S100A4-deficient mice (S100A4−/−) were
Both S100A4−/− mice and WT control littermates were given a single intraperitoneal injection of AOM followed by DSS treatment, and then colon tumorigenesis was monitored for 120 days (Fig. 4A). Compared with the WT control, we observed a significant decrease in the total colon tumor numbers in S100A4−/− mice, 11.3 ± 3.39 vs. 2.3 ± 1.63 (Fig. 4B and 4C). The maximal tumor diameters were notably smaller in S100A4−/− mice compared with WT controls, 6.5 ± 1.87 vs. 0.83 ± 0.68 (Fig. 4D). Pathologic analysis confirmed the different tumor size in S100A4−/− mice compared to WT.
mice (Fig. 4E). Moreover, WT mice had many S100A4+ cells. The number of proliferating cells in tumor tissues decreased significantly in S100A4−/− mice compared with WT mice (Fig. 4E). Therefore, these results suggest a critical role of S100A4 in promoting CRC development.

To exclude the possibility that reduced tumor burden in S100A4−/− mice is not due to altered gut bacteria, the gut microbiota of S100A4−/− mice and WT control mice was assessed by counting bacterial colonies from mice feces in LB-Medium, and there was no significant difference of the number of bacterial colonies between mice feces from WT and S100A4−/− mice (Fig. S3). This suggests that the gut bacteria were not significantly altered in S100A4−/− mice comparing with WT control littermates.

**S100A4-deficient mice are resistant to DSS-induced colitis**

To define the role of S100A4 in colitis-induced inflammation, S100A4−/− mice were fed with 3% DSS in drinking water for 5 days, and susceptibility was monitored by measuring body weight, assessing stool consistency and rectal bleeding, and measuring colon length during both the acute (day 5) and recovery (days 9–20) stages of the disease. The results showed that WT mice developed continued body weight loss...
(Fig. 5A), diarrhea, and rectal bleeding (Fig. 5B), whereas S100A4−/− mice started to recover once DSS was omitted from the drinking water. This reduced inflammatory phenotype was further evidenced by the gross appearance of the colon on day 10 (Fig. 5C). The colons of S100A4−/− mice were much longer than those of WT mice (Fig. 5C, D).

To obtain further evidence of weakened inflammation in S100A4−/− mice, the colon tissue was histologically analyzed on day 15 following AOM administration. The colons of S100A4−/− mice contained markedly less infiltrating inflammatory cells and displayed significantly less ulceration and hyperplasia (Fig. 5E and F).

S100A4 deficiency leads to a decreased inflammatory response in colon tissue. We then test whether S100A4 deficiency protected mice from colitis-associated tumorigenesis by dampening immune cell activation and inflammatory responses upon DSS-treatment. We examined the histopathological changes that occur during early stages of tumor induction (on day 15 after AOM injection) and found that S100A4-deficient colons showed decreased infiltration of macrophages and polymorphonuclear granulocytes (PMNs) (Fig. 5G).

To further characterize the immune cell types associated with the induction of inflammatory responses in the colons of S100A4−/− mice, myeloid cells present in the colonic lamina propria were isolated at a later stage of colitis and were analyzed by flow cytometry. On day 15 after AOM injection, the cell percentages of all analyzed myeloid cell types (CD11b−/,
F4/80<sup>+</sup>, Gr-1<sup>+</sup>) in S100A4<sup>−/−</sup> mouse colons were significantly lower than those in WT colons, except CD11 c<sup>+</sup> cells (Fig. 5G). In addition, a dramatic decrease in the percentage of F4/80<sup>+</sup> macrophages was evident in the mesenteric lymph nodes (MLN) of S100A4<sup>−/−</sup> mice (Fig. 5G). However, there were no significant differences of percentages of CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells both in colons and MLNs between S100A4<sup>−/−</sup> and WT mice (Fig. S4). Consistent with the decreased infiltration and activation of myeloid cells in the absence of S100A4<sup>−/−</sup> mice, the production of proinflammatory cytokines such as monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-2 (MIP-2), tumor necrosis factor (TNF)-α, IL (interleukin)-17 A, IL-6, interferon (INF)-γ and granulocyte-macrophage colony-stimulating factor (GMSF) were all found to be decreased in the colons of S100A4<sup>−/−</sup> mice relative to the levels found in WT mice (Fig. 5H). Taken together, these results indicate that S100A4 plays a critical role in promoting the inflammatory response in myeloid cells, especially in macrophages during DSS-induced colitis.

**Nuclear factor (NF)-κB signaling in macrophage is critical for promoting colon tumorigenesis**

The expression of tumorigenic and proinflammatory genes is modulated by signal transduction pathways such as NF-κB, extracellular receptor kinase (ERK), and signal transducer and activator of transcription 3 (STAT3) pathways. To understand whether these pathways and molecules were deregulated in the absence of S100A4, we examined the activation of inflammatory signaling pathways by Western blotting. Indeed, the NF-κB, ERK levels in AOM/DSS-induced colon tissues in S100A4<sup>−/−</sup> mice were clearly down-regulated compared with
those in WT mice (Fig. 6A). Consistent with the results of Western blotting, the expression of p-p65 in colon tissues in S100A4−/− mice was also down-regulated as revealed by immunofluorescence detection (Fig. 6B).

Down-regulation of the NF-κB pathways is associated with a decreased proliferation of epithelial cells in the hyperplastic colon regions of AOM/DSS-treated S100A4−/− mice (Fig. 6C). By contrast, untreated colon tissues of both S100A4−/− and WT mice displayed similar proliferation levels as measured by Ki67 staining (data not shown).

To identify the molecular mechanisms underlying the effects of extracellular S100A4 on the induction of inflammation, macrophage cell line Raw cells were cultured with different stimuli as indicated previously and were performed for the analysis of pathway-related genes. After treatment with S100A4 for various times (Fig. 6D), we found that phosphorylated p65 and IκBα were up-regulated compared with those in the control group. The phosphorylation level of ERK was unaffected. Thus, these results indicate that S100A4 promotes the activation of NF-κB signaling in macrophages.

The receptor of advanced glycation end products (RAGE) is an interaction partner for S100A4. Next, we tested whether S100A4-induced NF-κB signaling in Raw cells was RAGE dependent. The expression of RAGE in Raw cells was validated by Western blotting (Fig. 6D). We used a RAGE-specific inhibitor (FPS-ZM1) to prevent RAGE activation in cultured Raw cells and found that the level of phosphorylated NF-κB could not be up-regulated by S100A4 stimulation (Fig. 6E), suggesting that S100A4-activated NF-κB signaling in Raw cells was a RAGE-dependent process.

**Targeting S100A4 by S100A4-neutralizing antibody attenuates colitis and prevents CAC in a murine model**

Because S100A4 plays an important role in colitis pathogenesis, we examined the therapeutic value of S100A4 neutralizing antibody in mouse models. By administering S100A4 neutralizing...
antibody or an isotypic control (mIgG) preventively to the DSS-treated mice (during the DSS induction process), we found that S100A4 neutralizing antibody significantly alleviated the disease severity (Fig. 7A). Body weight loss was dramatically reduced in the neutralizing antibody-treated group compared with that in the mIgG treatment group (Fig. 7B and 7C). Consistent with the observation in the colitis model of S100A4¡¡/¡mice, we found a decrease in macrophage infiltration in neutralizing antibody-treated mice (Fig. 7D and 7E). These data indicate that neutralizing antibody could be an efficient treatment for colitis.

Furthermore, because S100A4 neutralizing antibody treatment appeared to ameliorate the inflammatory response in colitis, we then tested whether it could protect mice with colitis from developing tumors by treating CRC mice with either mIgG or neutralizing antibody during the DSS induction process. Interestingly, the tumor incidence and tumor volume were drastically reduced in S100A4 neutralizing antibody-treated mice (Fig. 7F-H). Collectively, these data indicate the therapeutic value of anti-S100A4 antibody in treating colitis and preventing CRC.

**Discussion**

In this study, we have demonstrated that S100A4 promotes colitis-associated colon tumorigenesis by enhancing the inflammatory response. S100A4 is expressed in CRC both in patients and experimental mouse models. The selective depletion of S100A4-expressing cells and deficiency in S100A4 attenuated colitis and prevented colon tumorigenesis in mice using the
AOM/DSS model. The colonic macrophage infiltrate and the production of cytokines in S100A4+/− mice were significantly decreased after DSS treatment. Further studies revealed that reduced colon inflammation and colorectal tumor development in S100A4−/− mice were partly due to the dampening NF-κB activation in macrophages.

A large number of reports have demonstrated that increased S100A4 is significantly correlated with tumor angiogenesis, cell survival, motility, invasion and metastasis.27,28 High S100A4 levels in colorectal tumors are associated with aggressive growth, metastasis, poor prognosis, and shortened patient survival times.33 However, its role in colon cancer progression remains to be adequately tested. Using an AOM/DSS-induced CRC model, we also detected a high level of S100A4 expression in the colon during the process of CRC (Fig. 1D). Further study has demonstrated that S100A4+ cells play critical roles in tumorigenesis as the depletion of S100A4-positive cells attenuates colitis and decreases the incidence of colon tumorigenesis. In addition, we found similar results to those of mice deficient in S100A4, indicating the important role of S100A4 molecules in disease progression. This work demonstrates that S100A4 plays an important and direct role in promoting CRC development in vivo.

It is becoming increasingly clear that cytokines and growth factors released during chronic inflammation contribute to tumorigenesis.13 In IBD, chronic inflammation causes the release of cytokines, growth factors, proteases, and reactive oxygen species (ROS).12 Cytokines released during inflammation may promote cancer development via the activation of NF-κB, which is one of the few key regulatory signaling molecules whose aberrant activation is invariably associated with inflammation and cancer.42 It has been reported that IKKβ-driven NF-κB activation in intestinal epithelial cells (IECs) is essential for the development of colonic adenomas in the AOM/DSS-induced CRC model.43 In addition, IKKβ-driven NF-κB activation in certain myeloid cells, most likely macrophages of the lamina propria, contributes to CRC development by the enhancing proliferation of pre-malignant IECs via stimulating the secretion of growth factors.43 In this study, we found that, during the process of AOM/DSS-induced CRC, many S100A4+ cells infiltrate into the inflammatory colon. The depletion of S100A4+ cells or S100A4 deficiency significantly dampens DSS-induced colitis. Inflammatory cell infiltration, especially that of macrophages, and the levels of cytokines such as IL-6, TNF-α, IL-17A and MCP-1, were also decreased obviously in S100A4−/− mice, a finding that is consistent with previous studies that S100A4 recruits macrophages.44 Furthermore, the NF-κB levels in AOM/DSS-induced colon tissues in S100A4−/− mice were clearly down-regulated compared with those in WT mice. In vitro, S100A4 could activate the NF-κB signal pathway in macrophages, contributing to the development of CRC by enhancing the proliferation of pre-malignant IECs. Thus, we elucidated a new mechanism that bridges chronic inflammation to CRC promotion. In addition, S100A4 neutralization significantly dampened DSS-induced colitis and decreased the incidence of colon tumorigenesis (Fig. 7). S100A4 could be a target for CRC therapy. S100A4 blockade may be useful in reducing the risk of colitis-associated colon cancer.

S100A4 expression was initially characterized in the cells of mesenchymal origin, including stromal fibroblasts and epithelial cells undergoing epithelial-mesenchymal transition (EMT). Recently, it was found that S100A4+ cells in liver were a subtype of macrophages.23 However, it seems that S100A4 is expressed in different types of cells in various tissues.45,46 The cellular origin of S100A4 in the colon is not clear. We found many types of stromal cells expressed S100A4 in colon tissues after DSS induction. Of the S100A4+ cells, approximately 97.9% were CD45−, 54.3% were CD11b−, 44.2% were F4/80−, and 25.7% were CD11 c+. In addition, only a small number of B cells, T cells and granulocytes expressed S100A4 (figure 1D). However, the role of different type of S100A4+ cells in colon and CRC still needs further study.

S100A4 controls a variety of intra- and extracellular processes. Intracellular S100A4 influences the function of distinct targets, such as different cytoskeletal-associated molecules and the tumor suppressor p53 protein, which promotes p53 degradation.47 Intracellular S100A4 is involved in a wide range of biological functions, such as the regulation of angiogenesis, cell survival, motility, invasion or metastasis.26,27 However, S100A4 could also serve as an extracellular cytokine, and its role in the soluble form has received increasing attention. The secretion of S100A4 by tumor and stromal cells is believed to serve as a key player in the metastasis of cancer cells or affecting angiogenesis.28,30 Although we did not know which form of S100A4 plays more important roles in colon tumorigenesis, our IHC staining of colon tumors suggests the weak intracellular staining, and our functional studies support a major source of myeloid cell-producing S100A4 during colon cancer development. It is certainly also important to analyze the role of intracellular S100A4 in myeloid cells during the development of colon tumorigenesis in the future.

In summary, this study provides in vivo evidence for a critical role of S100A4 in promoting colitis-related colon tumorigenesis and crosstalk between colitis, macrophages, S100A4, and CRC. It would be interesting to test further whether anti-S100A4 antagonists might be effective at targeting tumor-initiating cells as well as the tumor microenvironment, therefore providing a promising strategy for colon cancer prevention and treatment.

Materials and methods

Cell lines and mice

The murine colon cancer cell line CT26 was obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). These cells were cultured in RPMI 1640 medium containing 10% fetal calf serum at 37 °C with 5% CO2.

S100A4+/−-GFP and S100A4-deficient mice (S100A4−/−) mice were purchased from the Jackson Laboratory (Bar Harbor, ME). S100A4-TK transgenic mice were obtained from Dr. Eric G. Neilson (Northwestern University, Feinberg School of Medicine). All mice and WT control littermates were bred under specific pathogen-free conditions in the animal facilities at the Institute of Biophysics, Chinese Academy of Sciences. Male mice 8–10 weeks of age were used. This study was carried out in strict accordance with
the recommendations in the Guide for the Care and Use of Laboratory Animals of the Chinese Academy of Sciences. The experiments described were approved by the Institutional Animal Care and Use Committee of the Institute of Biophysics, Chinese Academy of Sciences.

**Induction of DSS-induced colitis**

Acute colitis was induced with 3% (w/v) DSS (molecular mass, 36–40 kDa; MP Biologicals) dissolved in sterile, distilled water for 5 days followed by normal drinking water until the end of the experiment. The DSS solutions were made fresh on day 3.

In the antibody preventive treatment experiment, mice were injected i.p. with S100A4-neutralizing antibody or control murine IgG (mIgG) at a dose of 10 mg/kg body weight on day 1 and day 5.

**Clinical scoring of colitis**

Scoring for stool consistency and occult blood was performed as previously described. Briefly, stool scores were determined as follows: 0 = well-formed pellets, 1 = semiformalized stools that did not adhere to the anus, 2 = semiformalized stools that adhered to the anus, and 3 = liquid stools that adhered to the anus. Bleeding scores were determined as follows: 0 = no blood by using hemoccult (Beckman Coulter), 1 = positive hemoccult, 2 = blood traces in stool visible, and 3 = gross rectal bleeding. Stool consistency scores and bleeding scores were added and presented as clinical scores.

**Induction of colorectal cancer**

Mice were injected intraperitoneally with 10 mg/kg AOM (Sigma). After 5 days, 2% DSS was given in drinking water over 5 days followed by regular drinking water for 2 weeks. This cycle was repeated 3 times, and mice were sacrificed 120 days after AOM injection. The S100A4 neutralizing antibody or control mIgG was injected i.p. at 10 mg/kg body weight twice during each DSS feeding period. Monoclonal anti-mouse S100A4 mAb was generated by immunizing BALB/c mice with S100A4 proteins. Using immune spleen cells and the mouse myeloma Sp2/0 cell line as fusion partner, hybridomas were generated and selected using standard published techniques.

**Depletion of S100A4-positive cells in S100A4-TK mice**

Every week, S100A4-TK mice and control littermates were given 50 mg/kg ganciclovir (GCV) (HuBeiKeYi Pharmaceutical Corporation, China) dissolved in saline i.p. every other day, during the 2 weeks of the regular drinking water period in the process of colorectal cancer induction as shown in Fig. 3A.

**Isolation and subsequent analysis of murine lamina propria lymphocytes**

According to the method of Weigmann et al., mouse colons were removed and cleaned. The colons were first predigested with 5 mmol/L EDTA and 1 mmol/L dithiothreitol. Next, the intraepithelial lymphocytes were discarded, and the colons were then digested with 0.05 g of collagenase D (Roche, Basel, Switzerland) and 0.05 g of DNase I (Sigma-Aldrich). The lamina propria lymphocytes were isolated using a 40/80 Percoll gradient.

**Flow cytometry analysis**

Single-cell suspensions prepared directly from the MLN, spleen and colon lamina propria were stained with the following directly labeled mouse-specific mAbs: Percp/Cy5.5-labeled anti-CD11b (clone M1/70), APC-labeled anti-Ly6 C (clone HK1.4), PE-labeled anti-F4/80 (clone BM8), Percp-labeled anti-CD4 (clone GK1.5), and APC-labeled anti-CD8 (clone 53–6.7). All antibodies were purchased from Biolegend and were used at a 0.2-µg/ml concentration. Cells were collected using a FACS Caliber system (BD Biosciences, San Diego, CA) and were analyzed using FlowJo software (TreeStar, Ashland, OR).

**Histopathological and immunohistochemical analysis**

The preparation of cryostat or paraffin tissue sections from mice was performed as described previously. The colon was rolled as a Swiss roll and fixed in 4% PFA. Paraffin-embedded sections were cut at 5 mm and were stained with HaE solution. Histological scores were evaluated by two independent investigators, blinded to the source of treatment, as follows: epithelium scores 0, normal morphology; 1, loss of goblet cells; 2, loss of goblet cells in large areas; 3, loss of crypts; and 4, loss of crypts in large areas. Infiltration scores were evaluated as follows: 0, no infiltrate; 1, infiltrate around the crypt basis; 2, infiltrate reaching the L. muscularis mucosae; 3, extensive infiltration reaching the muscularis mucosae and thickening of the mucosa; and 4, infiltration of the L. submucosa. The total histological score represents the sum of the epithelium and infiltration scores and ranges from 0 to 8. For immunohistochemistry (IHC), paraffin sections were incubated with anti-S100A4 (Abcam, Cambridge, UK), and frozen colon sections were incubated with anti-CD8, anti-CD4, anti-F4/80, anti-Gr-1 antibodies (BD Pharmingen, San Diego, CA), followed by incubation with species-matched Alexa dye-labeled or horseradish peroxidase (HRP)-conjugated secondary antibodies. Frozen colon sections were incubated with anti-S100A4 (Abcam, Cambridge, UK), anti-CD11b (BD Pharmingen, San Diego, CA), anti-F4/80 (BD Pharmingen, San Diego, CA), anti-α-SMA (Abcam, Cambridge, UK) antibodies and Alexa Fluor 488 and 555-conjugated secondary antibodies (Invitrogen, Grand Island, NY). Sections were evaluated under the microscope (DP71, OLYMPUS) for bright-field and fluorescence microscopy.

**Cytokine and serum biochemical analysis**

To detect multiple cytokines in the colons, tissues were homogenized in ice-cold TE buffer. Homogenates were centrifuged at 12,000 × g for 15 minutes. The supernatant was collected, and the ProcartaPlex™ multiplex immunoassay (Luminex) (eBioscience) was used on a Bioplex-200 system.
with the Bioplex Manager 5.0 software. The cytokines were analyzed according to the manufacturer’s protocol. S100A4 in cell culture supernatant and whole colon lysate were detected by sandwich ELISA as described previously.21

**Western blotting**

Tissue and cell extracts were analyzed using the following primary antibodies: anti-α-SMA, anti-S100A4, anti-pro-Collagen I (Santa Cruz Biotechnology, Santa Cruz, CA), anti-c-myb (ImmunoWay, Newark, DE) and anti-β-actin (Cell Signaling, Danvers, MA). HRP-conjugated goat anti-mouse or goat anti-rabbit IgG were used as secondary antibodies.

**Quantitative and statistical analysis**

All the data were expressed as means ± SEM and were analyzed using GraphPad Prism software. Differences between the two groups were compared using a two-tailed unpaired Student’s t-test or Mann-Whitney U test analysis. Other data were analyzed using one-way or 2-way ANOVA followed by Bonferroni’s multiple comparisons test. For all tests, a P value < 0.05 was considered statistically significant.

**Abbreviations**

- AOM: azoxymethane
- CAC: colitis-associated colorectal cancer
- CCL5: chemokine (C-C motif) ligand 5
- CD: Crohn’s disease
- CRC: colorectal cancer
- DSS: dextran sulfate sodium
- EMT: epithelial-mesenchymal transition
- ERK: extracellular receptor kinase
- GCV: ganciclovir
- GMCSF: granulocyte-macrophage colony-stimulating factor
- HCC: hepatocellular carcinoma
- IL: interleukin
- INF: interferon
- MAPK: mitogen-activated protein kinase
- MCP: monocyte chemotactic protein
- MIP: macrophage inflammatory protein
- MLN: mesenteric lymph nodes
- NF: nuclear factor
- PMNs: polymorphonuclear granulocytes
- RAGE: receptor of advanced glycation end products
- S100A4<sup>+/−</sup>: S100A4-deficient
- STAT3: signal transducer and activator of transcription 3
- TK: thymidine kinase
- TNF: tumor necrosis factor
- UC: ulcerative colitis
- VEGF: vascular endothelial growth factor
- WT: wild-type

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

We thank Dr. Kunsong (Chinese Academy of Sciences) and Jun Wang (Yale University) for discussions and technical help.

**Funding**

This work was supported by the Ministry of Science and Technology of China (2015CBB533705), the National Natural Science Foundation of China (81541051) and the Natural Science Foundation of Beijing (7162116).

**Authors’ contributions**

J.Z. and Z.C. were involved in the study design. J.Z., S.H., Q.Y. and J.J. collected data. J.Z., S.H., J.G., T.T., and Z.C. analyzed and interpreted the data. J.Z., Z.Q. and Z.C. wrote the manuscript.

**ORCID**

Jinhua Zhang http://orcid.org/0000-0001-8957-8893

**References**

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. doi:10.1016/j.cell.2011.02.013. PMID:21376230.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;444:420–60. doi:10.1038/nature05322. PMID:12490959.
3. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:434–41. doi:10.1038/nature07205. PMID:18650914.
4. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144:512–27. doi:10.1053/j.gastro.2013.01.002. PMID:23313965.
5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi:10.3322/caac.21332. PMID:26742998.
6. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J. Gastroenterol. 2008;14:5378–89. doi:10.3745/wjg.v14.i43.78. PMID:18200660.
7. Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol. 2013;35:229–44. doi:10.1007/s00281-013-0356-2. PMCID:PMC3568220.
8. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012;143:382–9. doi:10.1053/j.gastro.2012.04.054. PMID:22609382.
9. Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol. 2012;3:107. doi:10.3389/fimmu.2012.00107. PMID:22586430.
10. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:826–35. PMID:11247898.
11. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther. 2006;23:1097–104. doi:10.1111/j.1365-2036.2006.02854.x. PMID:16611269.
12. Klampfer L. Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets. 2011;11:451–64. PMID:21247378.
13. Grivennikov SI, Greten FR, Karin M. Inflammation, immunity, and cancer. Cell. 2010;140:883–99. doi:10.1016/j.cell.2010.01.025. PMID:20303878.
14. Nicolas-Avila JA, Adrover JM, Hidalgo A. Neutrophils in homeostasis, immunity, and cancer. Immunity. 2017;46:15–28. doi:10.1016/j.immuni.2016.12.012. PMID:28099862.
15. Berraondo P, Minute L, Ajona D, Corrales L, Melero I, Pio R. Innate immune mediators in cancer: between defense and resistance. Immunol Rev. 2016;274:290–306. doi:10.1111/imr.12464. PMID:27782320.

16. Lewis CE, Harney AS, Pollard JW. The Multifaceted role of perivascular macrophages in tumors. Cancer cell. 2016;30:18–25. doi:10.1016/j.ccell.2016.05.017. PMID:27441158.

17. Lewis CE, Harney AS, Pollard JW. The Multifaceted role of perivascular macrophages in tumors. Cancer cell. 2016;30:18–25. doi:10.1016/j.ccell.2016.05.017. PMID:27441158.

18. Boye K, Maehling MG, S100A4 and metastasis: a small actor playing many roles. Am J Pathol. 2010;176:528–35. doi:10.2353/ajpath.2010.090526. PMID:20019188.

19. Bressnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. Nat Rev Cancer. 2015;15:96–109. doi:10.1038/nrc3983. PMID:26541008.

20. Zhang J, Chen L, Liu X, Kammertoens T, Blankenstein T, Qin Z. Fibroblast-specific protein 1 (S100A4)-positive cells prevent carcinoma through collagen production and encapsulation of carcinogens. Cancer Res. 2013;73:2770–81. doi:10.1158/0008-5472.CAN-12-3022. PMID:23539497.

21. Zhong J, Chen L, Xiao M, Wang C, Qin Z. FSP1+ fibroblasts promote skin carcinogenesis by maintaining MCP-1-mediated macrophage infiltration and chronic inflammation. Am J Pathol. 2011;178:382–90. doi:10.1016/j.ajpath.2010.11.017. PMID:21224075.

22. Chen L, Li J, Zhang J, Dai C, Liu X, Wang J, et al. S100A4 promotes liver fibrosis via activation of hepatic stellate cells. J Hepatol. 2015;62:156–64. doi:10.1016/j.jhep.2014.07.035. PMID:25211176.

23. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, et al. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol. 1995;130:393–405. PMID:7816539.

24. Osterreicher CH, Penz-Osterreicher M, Grivennikov SI, Guma M, Koltsova EK, Datz C, et al. Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc Natl Acad Sci U S A. 2011;108:308–13. doi:10.1073/pnas.1017547108. PMID:21713249.

25. Mishra SK, Siddique HR, Saleem M. S100A4 calcium-binding protein is a key player in tumor progression and metastasis: preclinical and clinical evidence. Cancer metastasis reviews. 2012;31:163–72. doi:10.1007/s10555-011-9338-4. PMID:22109080.

26. Xue C, Plieth D, Venkov C, Xu C, Neilson EG. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res. 2003;63:3386–94. PMID:12810675.

27. Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, et al. Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res. 2014;20:187–98. doi:10.1158/1078-0432.CCR-13-1279. PMID:24240114.

28. Fabris L, Cadamuro M, Moserle L, Dzura J, Cong X, Sambolo L, et al. Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology. 2011;54:890–901. doi:10.1002/hep.24246. PMID:21861579.

29. Schmidt-Hansen B, Orre LM, Panizza E, Kaminskyy VO, Vernet E, Tompa P, et al. Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J. Pathol. 2003;200:589–95. doi:10.1002/path.1381. PMID:12898594.

30. Dahlmann M, Okhrimenko A, Marcinkowski P, Osterland M, Herrmann P, Smith J, et al. RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a promising biomarker for human colorectal cancer metastasis. Oncotarget. 2014;5:3220–33. doi:10.18632/oncotarget.908. PMID:24952599.

31. Vennios E, Chen F, Merlin D. NF-kappaB pathway in colitis-associated cancers. Transl Gastrointest Cancer. 2013;2:21–9. doi:10.3978/j.issn.2224-4778.2012.11.01. PMID:23626930.

32. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKBKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285–96. doi:10.1016/j.cell.2004.07.013. PMID:15294155.

33. Li ZH, Dulyaninova NG, House RP, Almo SC, Bresnick AR. S100A4 regulates macrophage chemotaxis. Mol Biol Cell. 2010;21:2598–610. doi:10.1091/mbc.E09-07-0609. PMID:20519440.

34. Cabezon T, Celis JE, Skibosh I, Klingelhofer J, Grigorian M, Gromov P, et al. Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer. Int. J. Cancer. 2007;121:1433–44. doi:10.1002/ijc.22850. PMID:17565747.

35. Xue C, Plieth D, Venkov C, Xu C, Neilson EG. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res. 2003;63:3386–94. PMID:12810675.

36. Kong P, Christia P, Saxena A, Su Y, Frangogiannis NG. Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and fibrosis. Am J Physiol Heart Circ Physiol. 2013;305:H1363–72. doi:10.1152/ajpheart.00395.2013. PMID:23997102.

37. Orre LM, Panizza E, Kaminskyy VO, Vernet E, Graslund T, Zhivotovsky B, et al. S100A4 interacts with p53 in the nucleus and promotes p53 degradation. Oncogene. 2013;32:5531–40. doi:10.1038/onc.2013.213. PMID:23752197.

38. Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity. 2010;32:379–91. doi:10.1016/j.immuni.2010.03.003. PMID:20303296.

39. Sorensen JT, Bagnoli G, Olesen J, et al. The platelet membrane glycoprotein deficient in thrombocytopenia using a monoclonal hybridoma antibody. J Clin Invest. 1990;86:1311–8. doi:10.1172/JCI109983. PMID:6449521.

40. Moenal A, Kuijper R, “The Swiss roll”: a simple technique for histological studies of the rodent intestine. Lab Anim. 1981;15:57–9. PMID:7020218.